Premier Biotech Acquires National Test Systems

November 5, 2025

Premier Biotech, a portfolio company of Align Capital Partners, has acquired National Test Systems (NTS), a provider of rapid point-of-care drug screening supplies and services that serves more than 1,500 facilities across the United States. The acquisition expands Premier's point-of-care testing capabilities (including oral fluid testing) and deepens its presence in government and behavioral health end markets; NTS CEO Andrew Panico will remain involved to support the transition.

Buyers
Premier Biotech, Align Capital Partners
Targets
National Test Systems
Platforms
Premier Biotech
Industry
Medical Devices
Location
Florida, United States
Transaction Type
Addon

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.